Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
2/3期
提前终止
NCT04815967
| 适应症 | Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury |
|---|
| 分期 | 2/3期 |
|---|
| 申办方 | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 32 人 |
|---|
| 干预（药物） | Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo |
|---|
| 开始日期 | 2021年11月2日 |
|---|
| 完成日期 | 2023年4月23日 |
|---|
| 结果公布日 | 2026年5月27日 |
|---|
摘要
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial.
The Change From Baseline in Modified Ashworth Scale (MAS) Score for Tone of the Primary Target Muscle Group (PTMG) Selected for Treatment at Week 4 Post-injection.
Baseline and Week 4 · units on a scale
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.90 ± 0.568 units on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 2.82 ± 0.405 units on a scale |
|---|
| Phase 2 (DBP); Placebo | 2.73 ± 0.467 units on a scale |
|---|
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.05 ± 0.762 units on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 1.82 ± 0.681 units on a scale |
|---|
| Phase 2 (DBP); Placebo | 2.65 ± 0.580 units on a scale |
|---|
The Clinical Global Impression of Change (CGI-C) Score in Functional Ability at Week 4 Post-injection.
Week 4 · score on a scale
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.4 ± 0.70 score on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 2.6 ± 0.67 score on a scale |
|---|
| Phase 2 (DBP); Placebo | 3.3 ± 0.48 score on a scale |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。